WO2007149827A3 - Method for modulating the pharmacokinetics and metabolism of a therapeutic agent - Google Patents

Method for modulating the pharmacokinetics and metabolism of a therapeutic agent Download PDF

Info

Publication number
WO2007149827A3
WO2007149827A3 PCT/US2007/071510 US2007071510W WO2007149827A3 WO 2007149827 A3 WO2007149827 A3 WO 2007149827A3 US 2007071510 W US2007071510 W US 2007071510W WO 2007149827 A3 WO2007149827 A3 WO 2007149827A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic agent
pharmacokinetics
metabolism
modulating
agent
Prior art date
Application number
PCT/US2007/071510
Other languages
French (fr)
Other versions
WO2007149827A2 (en
Inventor
Gary M Eichenbaum
Original Assignee
Janssen Pharmaceutica Nv
Gary M Eichenbaum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv, Gary M Eichenbaum filed Critical Janssen Pharmaceutica Nv
Priority to EP07812192A priority Critical patent/EP2037954A4/en
Publication of WO2007149827A2 publication Critical patent/WO2007149827A2/en
Publication of WO2007149827A3 publication Critical patent/WO2007149827A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention is a method for enhancing the activity of a therapeutic agent comprising the administration of the agent in combination with an enzyme, whereby a metabolic pathway of the therapeutic agent is counteracted and the agent's pharmacokinetics and metabolism are modulated.
PCT/US2007/071510 2006-06-20 2007-06-19 Method for modulating the pharmacokinetics and metabolism of a therapeutic agent WO2007149827A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07812192A EP2037954A4 (en) 2006-06-20 2007-06-19 Method for modulating the pharmacokinetics and metabolism of a therapeutic agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81522306P 2006-06-20 2006-06-20
US60/815,223 2006-06-20

Publications (2)

Publication Number Publication Date
WO2007149827A2 WO2007149827A2 (en) 2007-12-27
WO2007149827A3 true WO2007149827A3 (en) 2009-04-23

Family

ID=38834295

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/071510 WO2007149827A2 (en) 2006-06-20 2007-06-19 Method for modulating the pharmacokinetics and metabolism of a therapeutic agent

Country Status (2)

Country Link
EP (1) EP2037954A4 (en)
WO (1) WO2007149827A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102097026B (en) * 2009-12-14 2013-04-10 中国科学院上海药物研究所 Device and method for simulating pharmacokinetics characteristics in vitro

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877158A (en) * 1993-09-22 1999-03-02 Behringwerke Aktiengesellschaft Pro-prodrugs, their production and use
US5955100A (en) * 1992-10-27 1999-09-21 Behringwerke Aktiengesellschaft Prodrugs their preparation and use as pharmaceuticals
US5985281A (en) * 1994-12-23 1999-11-16 Zeneca Limited Chemical compounds
US20040082639A1 (en) * 2002-05-15 2004-04-29 Ho Chih Yung N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders
US20050025709A1 (en) * 2003-06-13 2005-02-03 Immunomedics, Inc. D-amino acid peptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5279824A (en) * 1988-04-14 1994-01-18 Merck Patent Gmbh Pharmaceutical formulation containing heparin and endo-beta-glucuronidase, useful for the treatment of thrombosis
US20040071685A1 (en) * 2002-10-09 2004-04-15 Devin Houston Compositions and methods for increasing the bioavailability of plant polyphenols
US7871607B2 (en) * 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20080312162A1 (en) * 2004-10-08 2008-12-18 The Ohio State University Methods and Compositions for Enzyme-Specific Activation of Carbohydrate-Conjugated Prodrugs

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955100A (en) * 1992-10-27 1999-09-21 Behringwerke Aktiengesellschaft Prodrugs their preparation and use as pharmaceuticals
US5877158A (en) * 1993-09-22 1999-03-02 Behringwerke Aktiengesellschaft Pro-prodrugs, their production and use
US5985281A (en) * 1994-12-23 1999-11-16 Zeneca Limited Chemical compounds
US20040082639A1 (en) * 2002-05-15 2004-04-29 Ho Chih Yung N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders
US20050025709A1 (en) * 2003-06-13 2005-02-03 Immunomedics, Inc. D-amino acid peptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2037954A4 *

Also Published As

Publication number Publication date
EP2037954A4 (en) 2011-09-14
WO2007149827A2 (en) 2007-12-27
EP2037954A2 (en) 2009-03-25

Similar Documents

Publication Publication Date Title
IL209979A (en) Use of hsp 70 for the preparation of a medicament for the treatment of a lysosomal storage disorder
WO2007146426A3 (en) Nanoshells for drug delivery
WO2007002390A3 (en) Compositions and methods for modulation of smn2 splicing
EP1835934A4 (en) Enzyme modulators and treatments
EP1740197A4 (en) Therapeutic enzyme formulations and uses thereof
WO2005111238A3 (en) Aptamer-mediated intracellular delivery of therapeutic oligonucleotides
WO2007019554A3 (en) Polysaccharides for delivery of active agents
WO2008112525A3 (en) Treatment of lysosomal storage diseases
WO2006063055A3 (en) Enzyme conjugates for use as detoxifying agents
EP1463512A4 (en) Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
WO2009132050A3 (en) Auris formulations for treating otic diseases and conditions
SI1720872T1 (en) Aryl and heteroaryl-piperidinecarboxylate derivatives, the preparation and the use thereof in the form of faah enzyme inhibitors
WO2000061192A3 (en) Methods and compositions for the treatment of pancreatitis
WO2006041641A3 (en) Therapeutic agents with decreased toxicity
WO2006124892A3 (en) Modulators of alpha-synuclein toxicity
WO2005108428A3 (en) Cd40 splice variants and their uses
WO2005074655A3 (en) Materials and method for promotion of nerve regeneration
WO2005105081A3 (en) Therapeutic formulations of desoxyepothilones
WO2006012521A3 (en) Treatment for ocular disease
WO2005045055A3 (en) The use of plp with peg-rmetase in vivo for enhanced efficacy
WO2007002188A3 (en) Mptenakts as modifiers of the pten/akt pathway and methods of use
WO2007149827A3 (en) Method for modulating the pharmacokinetics and metabolism of a therapeutic agent
WO2007041397A3 (en) Targeted pharmaceuticals and ligands
WO2006009947A3 (en) Migfs as modifiers of the igf pathway and methods of use
WO2005020954A3 (en) Proton pump inhibitor formulations, and methods of preparing and using such formulations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07812192

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007812192

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE